If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX(1-800-545-5979)
Humulin®
- Full Prescribing Information
Humulin® R (U-100) (regular insulin human injection, USP [rDNA origin])
100 units/mL - Full Prescribing Information
Humulin® R (U-500) (regular U-500 [concentrated] insulin human injection, USP [rDNA origin])
500 units/mL - Full Prescribing Information
Humulin® 70/30 (70% human insulin isophane suspension and 30% human insulin injection [rDNA origin])
100 units/mL - Full Prescribing Information
Humulin® N U-100 (human insulin [rDNA origin] isophane suspension)
100 units/mL
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
HUMULIN® R U-500 (insulin human injection): Route of Administration
Humulin R U-500 should be injected subcutaneously into the thigh, upper arm, abdomen, or buttocks.
Patients should inject their prescribed dose of U-500R SC into the
thigh
upper arm
abdomen, or
buttocks.
Injection sites should be rotated within the same region from one injection to the next to reduce the risk of lipodystrophy. Do not administer U-500R IV or IM.
The efficacy and safety of U-500R delivered by CSII has not been determined.
Enclosed Prescribing Information
HUMULIN® R U-500 (insulin human injection), for subcutaneous use, Lilly
Glossary
CSII = continuous subcutaneous insulin infusion
IM = intramuscular
IV = intravenous
SC = subcutaneous
U-500R = Humulin® R U-500 (insulin human injection) 500 units/mL
Date of Last Review: June 06, 2019
Contact Lilly
Call Us
If you need information about a Lilly product or want to report an Adverse Event or Product Complaint, you may call us.
Available Mon - Fri, 9am - 7pm EST